Zoetis (ZTS) Liabilities and Shareholders Equity (2012 - 2026)
Zoetis' (ZTS) quarterly Liabilities and Shareholders Equity came in at $15.1 billion in Q2 2026, up 4.13% year-over-year from $14.5 billion in Q2 2025, and down 0.51% quarter-over-quarter from $15.2 billion in Q1 2026.
Analysis
Zoetis (ZTS) Liabilities and Shareholders Equity (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Liabilities and Shareholders Equity for 15 consecutive years, with $15.1 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Liabilities and Shareholders Equity rose 4.13% year-over-year to $15.1 billion in Q2 2026; TTM through Jun 2026 was $60.9 billion, a 6.49% increase from a year earlier, with the FY2025 full-year figure at $15.5 billion, up 8.8% from the prior year.
- Liabilities and Shareholders Equity was $15.1 billion for Q2 2026 at Zoetis, down from $15.2 billion in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $15.5 billion in Q4 2025 and troughed at $13.7 billion in Q3 2022.
- A 5-year average of $14.4 billion and a median of $14.3 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity fell 4.19% in 2023 and increased 8.8% in 2025, its largest moves.
- Over 5 years, Liabilities and Shareholders Equity stood at $14.9 billion in 2022, then decreased by 4.19% to $14.3 billion in 2023, then fell by 0.44% to $14.2 billion in 2024, then rose by 8.8% to $15.5 billion in 2025, then declined by 2.67% to $15.1 billion in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $15.1 billion (Q2 2026), $15.2 billion (Q1 2026), and $15.5 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.69 Bn | 40.49 Bn | 779.09 Mn | 3.44 Bn |
| 2 | Zoetis | 30.63 Bn | 28.95 Bn | 1.05 Bn | 15.08 Bn |
| 3 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | 13.56 Bn |
| 4 | Phibro Animal Health | 1.49 Bn | 1.41 Bn | 134.40 Mn | 1.50 Bn |
| 5 | Immucell | 90.19 Mn | 81.33 Mn | 2.44 Mn | 46.63 Mn |
| 6 | Zhengye Biotechnology Holding | 76.23 Mn | 69.14 Mn | - | 61.54 Mn |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - | 539,261.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 15.08 Bn |
| Mar 31, 2026 | 15.15 Bn |
| Dec 31, 2025 | 15.49 Bn |
| Sep 30, 2025 | 15.16 Bn |
| Jun 30, 2025 | 14.48 Bn |
| Mar 31, 2025 | 14.10 Bn |
| Dec 31, 2024 | 14.24 Bn |
| Sep 30, 2024 | 14.36 Bn |
| Jun 30, 2024 | 14.17 Bn |
| Mar 31, 2024 | 14.35 Bn |
| Dec 31, 2023 | 14.30 Bn |
| Sep 30, 2023 | 14.11 Bn |
| Jun 30, 2023 | 13.75 Bn |
| Mar 31, 2023 | 13.75 Bn |
| Dec 31, 2022 | 14.93 Bn |
| Sep 30, 2022 | 13.67 Bn |
| Jun 30, 2022 | 13.77 Bn |
| Mar 31, 2022 | 13.86 Bn |
| Dec 31, 2021 | 13.90 Bn |
| Sep 30, 2021 | 13.71 Bn |